Clinical trial
A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors
NCT04060342 is registered in ClinicalTrials.gov with GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors
- Lead sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 13, 2019
- Completion date
- April 11, 2022
- Enrollment
- 61 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
castration-resistant prostate cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, microsatellite stable colorectal cancer, non-small cell lung cancer, pancreatic adenocarcinoma, renal cell carcinoma, small-cell lung cancer, triple negative breast cancer, urothelial carcinoma